Patents by Inventor Alan Hutchison

Alan Hutchison has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220043965
    Abstract: A computer-implemented electronic commons system for sharing information. The system including an electronic content management computer executing a stored program to implement the steps of (a) receiving electronic information content from users, the electronic information including identification of at least one author, (b) receiving instructions from users to organize multiple electronic information content into a handbook, (c) generating a handbook including the multiple electronic information content stored on a computer readable medium of the electronic content management computer based on the received instructions, (d) generating an attribution for the handbook, the attribution including the identifications of the authors of the constituent electronic information content in the handbook; and (e) displaying a representation of the attribution of the handbook.
    Type: Application
    Filed: July 28, 2021
    Publication date: February 10, 2022
    Inventors: Carl Dvorak, Alan Hutchison, Mike Lonergan, Janet L. Campbell, Anna Green, John Hansen, Kyle Bernard
  • Patent number: 8362286
    Abstract: Applicants have discovered a method for the stereoselective and regioselective synthesis of 3?-hydroxy, 3?-methyl-5?-pregnan-20-one (ganaxolone) comprising reacting 5?-pregnane-3,20-dione; with an organometallic methylating agent in an inert solvent to provide a compound of the formula
    Type: Grant
    Filed: August 11, 2010
    Date of Patent: January 29, 2013
    Assignee: Marinus Pharmaceuticals, Inc.
    Inventors: Kenneth Shaw, Alan Hutchison
  • Patent number: 7915288
    Abstract: 1-aryl-4-substituted isoquinoline or 1-aryl-3,4-disubstituted isoquinoline analogues of Formula I and Formula II, as follows: wherein R1, R2, R3, R8, R9, A and Ar are defined herein. Such compounds are ligands of C5a receptors. Preferred compounds of Formula I and II bind to C5a receptors with high affinity and exhibit neutral antagonist or inverse agonist activity at C5a receptors. The present invention also relates to pharmaceutical compositions comprising such compounds, and to the use of such compounds in treating a variety of inflammatory, cardiovascular, and immune system disorders. In addition, the present invention provides labeled 1-aryl-4-substituted isoquinolines or 1-aryl-3,4-disubstituted isoquinolines, which are useful as probes for the localization of C5a receptors.
    Type: Grant
    Filed: May 6, 2005
    Date of Patent: March 29, 2011
    Assignee: Novartis International Pharmaceutical Ltd.
    Inventors: Kyungae Lee, Jun Yuan, George D. Maynard, Alan Hutchison, Scott Mitchell
  • Publication number: 20110040112
    Abstract: Applicants have discovered a method for the stereoselective and regioselective synthesis of 3?-hydroxy, 3?-methyl-5?-pregnan-20-one (ganaxolone) comprising reacting 5?-pregnane-3,20-dione; with an organometallic methylating agent in an inert solvent to provide a compound of the formula
    Type: Application
    Filed: August 11, 2010
    Publication date: February 17, 2011
    Applicant: MARINUS PHARMACEUTICALS, INC.
    Inventors: Kenneth Shaw, Alan Hutchison
  • Publication number: 20100267698
    Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
    Type: Application
    Filed: January 5, 2010
    Publication date: October 21, 2010
    Inventors: Guiying Li, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu, George P. Luke, Scott Mitchell, Martin Patrick Allen, Spiros Liras
  • Patent number: 7642267
    Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I. The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
    Type: Grant
    Filed: November 19, 2007
    Date of Patent: January 5, 2010
    Assignee: Neurogen Corporation
    Inventors: Guiying Li, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu, George P. Luke, Scott Mitchell, Martin Patrick Allen, Spiros Liras
  • Publication number: 20090082362
    Abstract: Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given.
    Type: Application
    Filed: March 28, 2008
    Publication date: March 26, 2009
    Inventors: Rajagopal Bakthavatchalam, Alan Hutchison, Robert W. DeSimone, Kevin J. Hodgetts, James E. Krause, Geoffrey G. White
  • Publication number: 20080227793
    Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
    Type: Application
    Filed: November 19, 2007
    Publication date: September 18, 2008
    Inventors: Guiying Li, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu, George P. Luke, Scott Mitchell, Martin Patrick Allen, Spiros Liras
  • Publication number: 20080146546
    Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABAA receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.
    Type: Application
    Filed: February 4, 2008
    Publication date: June 19, 2008
    Inventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
  • Patent number: 7348326
    Abstract: Disclosed are compounds of the formula: or the pharmaceutically acceptable non-toxic salts thereof wherein the A, B, C, D, X, R1, R2, R3, R4, R5, and R6, are variables defined herein, which compounds are highly selective agonists, antagonists or inverse agonists for GABAa brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAa brain receptors, and are therefore useful in the diagnosis and treatment of anxiety, Down Syndrome, sleep, cognitive and seizure disorders, depression, overdose with benzodiazepine drugs, and enhancement of memory and alertness.
    Type: Grant
    Filed: December 6, 2005
    Date of Patent: March 25, 2008
    Assignee: Neurogen Corporation
    Inventors: Robert DeSimone, Alan Hutchison, Kenneth Shaw, Daniel Rosewater
  • Patent number: 7323478
    Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof wherein Q, X, Y, Z, and R1 R9, and R12-R19 are defined herein. These compounds are selective modulators of MCH 1 receptors that are, therefore, useful in the treatment of a variety of metabolic, feeding, and sexual disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also disclosed.
    Type: Grant
    Filed: April 8, 2004
    Date of Patent: January 29, 2008
    Assignee: Neurogen Corporation
    Inventors: Rajagopal Bakthavatchalam, Andrew Thurkauf, Alan Hutchison
  • Publication number: 20080009477
    Abstract: CB1 antagonists are provided. Such compounds may be used to modulate CB1 activity in vivo or in vitro, and are particularly useful in the treatment of conditions responsive to CB1 receptor modulation in humans, domesticated companion animals and livestock animals, including appetite disorders, obesity and addictive disorders. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using ligands for receptor localization studies and various in vitro assays.
    Type: Application
    Filed: November 1, 2005
    Publication date: January 10, 2008
    Applicant: NEUROGEN CORPORATION
    Inventors: Alan Hutchison, Jun Yuan
  • Patent number: 7300945
    Abstract: This invention relates to benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds, all of which may be described by of Formula I The invention is particularly related to such compounds that bind with high selectivity and high affinity to the benzodiazepine site of GABAA receptors. This invention also relates to pharmaceutical compositions comprising such compounds and to the use of such compounds in treatment of certain central nervous system (CNS) diseases. Novel processes for preparing compounds of Formula I are disclosed. This invention also relates to the use of benzimidazoles, pyridylimidazoles and related bicyclic heteroaryl compounds of Formula I in combination with one or more other CNS agents to potentiate the effects of the other CNS agents. Additionally this invention relates to the use such compounds as probes for the localization of GABAA receptors in tissue sections.
    Type: Grant
    Filed: July 12, 2005
    Date of Patent: November 27, 2007
    Assignee: Neurogen Corporation
    Inventors: Guiying Li, Pamela Albaugh, Kevin S. Currie, Guolin Cai, Linda M. Gustavson, Kyungae Lee, Alan Hutchison, George D. Maynard, Jun Yuan, Ling Hong Xie, Manuka Ghosh, Nian Liu, George P. Luke, Scott Mitchell, Martin Patrick Allen, Spiros Liras
  • Publication number: 20070249616
    Abstract: Compounds of Formula I are provided, in which variables are as described herein: Such compounds may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    Type: Application
    Filed: June 15, 2007
    Publication date: October 25, 2007
    Applicant: NEUROGEN CORPORATION
    Inventors: Alan Hutchison, Bertrand Chenard, James Tarrant, Guiying Li, Manuka Ghosh, George Luke, John Peterson, Wallace Pringle, Mary-Margaret O'Donnell, Kyungae Lee, Linda Gustavson, Dario Doller
  • Publication number: 20070043049
    Abstract: Substituted heterocyclic diarylamine analogues of Formula I are provided: wherein X, Y and Z are independently N or optionally substituted C, and other variables are as described in the specification. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
    Type: Application
    Filed: July 9, 2004
    Publication date: February 22, 2007
    Applicant: Neurogen Corporation
    Inventors: Rajagopal Bakthavatchalam, Kevin Hodgetts, Alan Hutchison, Robert Ohliger, Taeyoung Yoon, Xiaozhang Zheng
  • Publication number: 20070027155
    Abstract: Biaryl piperazinyl-pyridine analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.
    Type: Application
    Filed: July 16, 2004
    Publication date: February 1, 2007
    Inventors: Rajagopal Bakthavatchalam, Charles Blum, Harry Brielmann, Bertrand Chenard, Stephane De Lombaert, Kevin Hodgetts, Alan Hutchison, Taeyoung Yoon, Xiaozhang Zheng
  • Patent number: 7160879
    Abstract: Melanin concentrating hormone receptor ligands (especially substituted 2-(4-benzyl-piperazin-1-ylmethyl)-1H-benzoimidazole analogues), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    Type: Grant
    Filed: January 9, 2003
    Date of Patent: January 9, 2007
    Assignee: Neurogen Corporation
    Inventors: Robert W. DeSimone, John M. Peterson, Cheryl Steenstra, Yiping Shen, Linda M. Gustavson, Christopher Mach, Alan Hutchison
  • Publication number: 20060229298
    Abstract: Melanin concentrating hormone receptor ligands (especially 1-benzyl-4-aryl-piperazines, 1-benzyl-4-aryl-piperidines and related compounds), capable of modulating MCH receptor activity, are provided. Such ligands may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).
    Type: Application
    Filed: May 17, 2006
    Publication date: October 12, 2006
    Inventors: Alan Hutchison, Linda Gustavson, John Peterson, Dario Dollar, Timothy Caldwell, Taeyoung Yoon, Wallace Pringle, Rajagopal Bakthavatchalam, Yiping Shen, Cheryl Steenstra, Helen Yin, Robert DeSimone, Xiao-shu He
  • Publication number: 20060217384
    Abstract: Disclosed are compounds of the formula: and the pharmaceutically acceptable salts thereof, wherein W, Q, X, X1, Y and Z are as defined herein. These compounds bind with high selectivity and/or high affinity to the benzodiazepine site of GABAA receptors and are therefore useful in the treatment of central nervous system (CNS) diseases and as probes for the localization of GABAA receptors in tissue samples. Also disclosed are intermediates useful in the preparation of these compounds.
    Type: Application
    Filed: May 30, 2006
    Publication date: September 28, 2006
    Applicant: Neurogen Corporation, A Corporation of the state of Delaware
    Inventors: Jun Yuan, Pamela Albaugh, Kenneth Shaw, Alan Hutchison
  • Patent number: 7109351
    Abstract: Substituted pyrrolecarboxamide compounds are disclosed. These compounds are highly selective agonists, antagonists or inverse agonists for GABAA brain receptors or prodrugs of agonists, antagonists or inverse agonists for GABAA brain receptors and are therefore useful in the diagnosis and treatment of anxiety, depression, Alzheimer's dementia, sleep and seizure disorders, overdose with benzodiazepine drugs and for enhancement of memory. Pharmaceutical compositions, including packaged pharmaceutical compositions, are further provided. Compounds of the invention are also useful as probes for the localization of GABAA receptors in tissue samples.
    Type: Grant
    Filed: August 30, 2000
    Date of Patent: September 19, 2006
    Assignee: Neurogen Corporation
    Inventors: Pamela Albaugh, Kenneth Shaw, Alan Hutchison